ACP-204 is under clinical development by Acadia Pharmaceuticals and currently in Phase III for Psychosis. According to GlobalData, Phase III drugs for Psychosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how ACP-204’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACP-204 overview
ACP-204 is under development for the treatment of Alzheimer’s disease psychosis. It acts by targeting 5-HT2A. It is administered through oral route.
Acadia Pharmaceuticals overview
Acadia Pharmaceuticals (Acadia) discovers, develops, and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company’s marketed product Nuplazid (pimavanserin) is an FDA-approved drug for the treatment of Parkinson’s disease psychosis. It’s pipeline includes pimavanserin for the treatment of various indications which include Schizophrenia, major depressive disorder (MDD), dementia-related psychosis (DRP), and trofinetide for the treatment of Rett Syndrome. The company markets its product in the US. It has an operational presence in Denmark, Switzerland, and the UK. Acadia is headquartered in San Diego, California, the US.
For a complete picture of ACP-204’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
